Peter Blundell
Peter is a pharmacist by profession and joined the MHRA in January 2013.
Prior to joining the MHRA, Peter had worked in the pharmaceutical industry for over 30 years, focusing mainly on Pharmaceutical Wholesale and Retail Pharmacy.in various managerial roles including Operations Management, Regulatory Affairs, Quality Assurance and acted as Responsible Person for a number of companies in the UK.
Peter has experience in the implementation of ISO 9001 and ISO 13485 Quality Systems and is an ISO Pharmaceutical Lead Auditor.
He was an industry representative on the BAPW RP Committee, and was instrumental in identifying some of the more recent examples of falsified medicines and is a member of the MHRA Falsified Medical Product Stakeholders Group.
Related content and links
About the MHRA Inspectorate Blog
This blog shares the work of the Medicines and Healthcare products Regulatory Agency (MHRA) Inspectorate, by inspectors and those the Inspectorate works with.
Categories
Follow us on social media
Printing Posts
Other MHRA Blogs
Comments and moderation
Recent posts
- MHRA Good Clinical and Laboratory Practice Symposia (11 and 12 February 2025)
- Public Consultation on the International Council for Harmonisation ICH E6 (R3) Guideline for Good Clinical Practice Annex-2
- DSUR Submissions and Fees are Changing from 1 June 2024
- Pharmacovigilance unravelled: highlights of the 2024 MHRA GPvP Symposium
- Pilot GMP Single Inspection Program